Cost-effectiveness of lipid-lowering treatment according to lipid level

Canadian Journal of Cardiology

Volumn 21, Issue 8, 2005, Pages 681-687

  Pilote, Louise ^a   Ho, Vivian ^b   Lavoie, Frédéric ^a   Coupal, Louis ^a   Zowall, Hanna ^a   Grover, Steven A ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b RICE UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Cost effectiveness; Lipid lowering drugs; Prevention

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; LIPID; SIMVASTATIN;

ADULT; AGED; ARTICLE; CALCULATION; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG COST; FEMALE; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; POPULATION RESEARCH; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SAMPLING; SECONDARY PREVENTION;

ADULT; AGE DISTRIBUTION; AGED; ANTILIPEMIC AGENTS; CANADA; CARDIOVASCULAR DISEASES; CHOLESTEROL; COST-BENEFIT ANALYSIS; FEMALE; HEALTH SURVEYS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RISK FACTORS; SEX DISTRIBUTION; SIMVASTATIN;

EID: 22744432791     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
3. Sacks FM, Pfeffer MA, Moye, LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
6. Shepherd J. The West of Scotland Coronary Prevention Study: A trial of cholesterol reduction in Scottish men. Am J Cardiol 1995;76:113C-7C.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
8. West of Scotland Coronary Prevention Study Group. West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996;348:1339-42.
9. West of Scotland Coronary Prevention Study Group. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. Am J Cardiol 1995;76:485-91.
10. Pfeffer MA, Sacks FM, Moye LA, et al. Cholesterol and Recurrent Events: A secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol 1995;76:98C-106C.
11. Frohlich J, Fodor G, McPherson R, Genest J, Langner N, for the Dyslipidemia Working Group of Health Canada. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: Interim report. Can J Cardiol 1998;14(Suppl A):17A-21A.
12. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
13. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of siravastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997;336:332-6.
14. Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C. JAMA 1995;273:1032-8.
15. MacLean DR, Petrasovits A, Nargundkar M, et al. Canadian heart health surveys: A profile of cardiovascular risk. Survey methods and data analysis. Canadian Heart Health Surveys Research Group. CMAJ 1992;146:1969-74.
16. Grover SA, Coupal L, Paquer S, Zowall H. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: Forecasting the incremental benefits of preventive coronary and cerebrovascular events. Arch Intern Med 1999;159:593-600.
17. Grover SA, Paquet S, Levinton C, Coupal L, Zowall H, Estimating the benefits of modifying risk factors of cardiovascular disease: A comparison of primary vs secondary prevention. Arch Intern Med 1998;158:655-62. (Erratum in 1998;158:1228)
18. The Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: The Lipid Research Clinics Program Prevalence Study. Circulation 1979;60:427-39.
19. Heiss G, Tamir I, Davis CE, et al. Lipoprotein-cholesterol distributions in selected North American populations: The lipid research clinics program prevalence study. Circulation 1980;61:302-15.
20. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol towering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996;93:1796-802. (Erratum in 1996;94:849)
21. IMS Canada. Canadian Compuscript, January-December, 1996. Pointe Claire: IMS Canada, 1996.
22. Resource Intensity Weights. Summary of Methodology, 1996/97. Ottawa: The Canadian Institute for Health Information, 1996.
23. Jacobson TA, Schein JR, Williamson A, Ballantyne CM. Maximizing the cost,effectiveness of lipid-lowering therapy. Arch Intern Med 1998;158:1977-89.
24. Garner TI, Dardis R. Cost-effectiveness analysis of end-stage renal disease treatments. Med Care 1987;25:25-34.
25. Grover SA, Dorais M, Paradis G, et al. Lipid screening to prevent coronary artery disease: A quantitative evaluation of evolving guidelines. CMAJ 2000;163:1263-9.
26. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96:4211-8.
27. Haffner SM. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: Implications for the prevention of coronary heart disease. Diabetes Care 1997;20:469-71.
28. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20. (Erratum in 1997;20:1048)
29. Iglehart JK. The American health care system - expenditures. N Engl J Med 1999;340:70-6.
30. Pilote L, Saynina O, Lavoie F, McClellan M. Cardiac procedure use and outcomes in elderly patients with acute myocardial infarction in the United States and Quebec, Canada, 1988 to 1994. Med Care 2003;41:813-22.
31. Grover SA, Coupal L, Hu XP. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 1995;274:801-6.